Clinical Trial Update: Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir [Phase 1]

View source ↗

Summary

Phase 1 bioavailability study comparing 10 mg and 5 mg dolutegravir tablets with conventional tablets in HIV infections; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Dolutegravir (dolutegravir)

Snippet

Sponsor: ViiV Healthcare | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2018-12-21